Molecularly guided precision therapy in metastatic adamantinoma: a case report
Adamantinoma is a rare bone tumor characterized by a propensity for local recurrence and distant metastasis. Management of metastatic disease remains challenging owing to the absence of standardized therapy and the limited efficacy of conventional chemotherapy. This case report describes a young woman with adamantinoma harboring an XRCC2 frameshift mutation. She showed a sustained clinical response to fourth-line treatment with the PARP inhibitor olaparib, which lasted 15 months and led to improved performance status. Subsequent progression led to combination therapy with atezolizumab and bevacizumab, maintaining stable disease for eight months. Molecularly guided treatment resulted in an overall survival of 25 months.
Authors
- Sergey Orlov (ORCID: https://orcid.org/0000-0002-3134-1989)
- A. A. Musaelyan (ORCID: https://orcid.org/0000-0002-7570-2256)
- Евгений Наумович Имянитов (ORCID: https://orcid.org/0000-0003-4529-7891)
- Svetlana V. Odintsova (ORCID: https://orcid.org/0000-0001-5591-7746)
- A.O. Ivantsov
Institutions
- First Pavlov State Medical University of St. Petersburg (RU)
- Institute of Oncology NN Petrov (RU)
- Federal State Budgetary Scientific Institution Research Institute of Medical Primatology (RU)
- Cancer Research Center (US)
- St. Petersburg State Medical Academy "City Polyclinic №44" (RU)
- Cancer Genetics (United States) (US)
- Infinity (United States) (US)
- Saint Petersburg State Pediatric Medical University (RU)
Publication Details
- Journal
- Personalized Medicine
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/17410541.2025.2600909
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00